Sobi and Selecta announce closing of previously announced strategic licensing agreement for SEL-212, a phase 3-ready novel treatment for Chronic Refractory Gout
Stock Information for Selecta Biosciences Inc.
Loading
Please wait while we load your information from QuoteMedia.